Clinical and gut microbiota (GM) markers of aggressive carcinoid syndrome (CS)

#4330

Introduction: While most patients (pts) with CS present indolent disease (iCS), others have aggressive disease (aCS). Little is known about biomarkers of aCS.

Aim(s): To evaluate clinical and GM signatures of CS and its aggressiveness.

Materials and methods: Prospective cohort of metastatic neuroendocrine tumours (NET) pts with elevated urinary 5HIAA (CS group) and a control group (CG) of non-functioning NET pts. Clinical variables and fecal samples (analysed by shotgun metagenomics) were collected prior to or during somatostatin analogues (SSA) (T1) and upon progression (PD; T2). aCS was defined as carcinoid heart disease (CHD) onset and/or clinical and biochemical PD with or without radiological PD < 12 months from SSA start. Clinical PD was defined as CS aggravation requiring treatment change. Progression-free survival (PFS) was computed from first dose of SSA.

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Henrique K, Durant L, Iebba V, Derosa L,

Keywords: neuroendocrine tumour, carcinoid syndrome, gut microbiome,